Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00378-6955-01 00378-6955 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jul 9, 2015 In Use
42292-0007-10 42292-0007 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Apr 15, 2016 Jan 31, 2020 No Longer Used
00054-0399-25 00054-0399 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov 11, 2020 In Use
31722-0380-01 31722-0380 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 21, 2025 In Use
69238-1250-01 69238-1250 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sep 4, 2018 In Use
73190-0999-01 73190-0999 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov 21, 2024 In Use
42292-0007-01 42292-0007 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Apr 15, 2016 Jan 31, 2020 No Longer Used
68682-0002-60 68682-0002 Bexarotene Bexarotene 1.0 g/100g Hormonal Therapy Immunomodulator Retinoic Acid Derivative Topical Jun 28, 2000 In Use
43602-0176-01 43602-0176 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sep 6, 2024 In Use
73536-0500-01 73536-0500 ROPEGINTERFERON ALFA-2B BESREMi 500.0 ug/mL Immunotherapy Cytokine Interferon Subcutaneous Nov 12, 2021 In Use
73536-0511-01 73536-0511 ROPEGINTERFERON ALFA-2B BESREMi Pen 500.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Jun 25, 2026 In Use
00008-0100-01 00008-0100 Inotuzumab Ozogamicin Besponsa 0.25 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Aug 18, 2017 In Use
72579-0017-01 72579-0017 Sonrotoclax BEQALZI 5.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
72579-0025-02 72579-0025 Sonrotoclax BEQALZI 20.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
72579-0022-08 72579-0022 Sonrotoclax BEQALZI 80.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
72579-0020-01 72579-0020 Sonrotoclax BEQALZI 1.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
72579-0022-01 72579-0022 Sonrotoclax BEQALZI 80.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
72579-0025-01 72579-0025 Sonrotoclax BEQALZI 20.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
72579-0015-04 72579-0015 Sonrotoclax BEQALZI 1.0 mg/1, 5.0 mg/1, 20.0 mg/1, 80.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
63459-0348-04 63459-0348 Bendamustine Hydrochloride Bendeka 25.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec 8, 2015 In Use
71288-0102-10 71288-0102 Bendamustine HCl Bendamustine 25.0 mg/5mL Chemotherapy Alkylating Agent Purine analog Intravenous Jun 5, 2023 In Use
71288-0103-20 71288-0103 Bendamustine HCl Bendamustine 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jun 5, 2023 In Use
55150-0391-01 55150-0391 BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jun 5, 2023 In Use
60505-6096-00 60505-6096 Bendamustine hydrochloride Bendamustine Hydrochloride 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jun 19, 2023 Apr 30, 2025 No Longer Used
83703-0533-01 83703-0533 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec 15, 2022 In Use

Found 12611 results — Export these results